ATAI Life Sciences Reports Leadership Changes
Ticker: ATAI · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-officers
TL;DR
ATAI Life Sciences board and execs shuffled on Jan 19th.
AI Summary
On January 19, 2025, ATAI Life Sciences N.V. reported changes in its board of directors and executive officers. The filing details the departure of certain directors and officers, the election of new directors, and updates regarding compensatory arrangements for key personnel. This indicates a restructuring or strategic shift within the company's leadership.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, potentially affecting the company's stability and performance.
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- January 19, 2025 (date) — Date of earliest event reported
- Wallstraße 16, 10179 Berlin, Germany (address) — Principal executive offices
FAQ
What specific roles have been affected by the leadership changes at ATAI Life Sciences N.V.?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting a broad impact across directorial and officer positions.
When were these leadership changes effective or reported?
The date of the earliest event reported is January 19, 2025, and the filing was made as of January 24, 2025.
Are there any details on the reasons for the departure of directors or officers?
The provided text does not specify the reasons for the departure of any directors or officers.
What is the primary business of ATAI Life Sciences N.V. according to the filing?
ATAI Life Sciences N.V. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where are ATAI Life Sciences N.V.'s principal executive offices located?
The principal executive offices are located at Wallstraße 16, 10179 Berlin, Germany.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-24 16:15:48
Filing Documents
- ef20042036_8k.htm (8-K) — 26KB
- 0001140361-25-001894.txt ( ) — 160KB
- atai-20250119.xsd (EX-101.SCH) — 4KB
- atai-20250119_lab.xml (EX-101.LAB) — 22KB
- atai-20250119_pre.xml (EX-101.PRE) — 16KB
- ef20042036_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 19, 2025, Mr. Michael Auerbach resigned as a member of the supervisory board of directors (the "Supervisory Board") of atai Life Sciences N.V. (the "Company") and of the Supervisory Board's compensation committee. Mr. Auerbach's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies and practices. The Company thanks Mr. Auerbach for his service to the Company and its shareholders. Following Mr. Auerbach's resignation, effective January 19, 2025, the Supervisory Board decreased its size from seven to six directors.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: January 24, 2025 By: /s/ Srinivas Rao Name: Srinivas Rao Title: Chief Executive Officer